[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
November 1981

Effects of Clonidine on Anxiety Disorders

Author Affiliations

From the Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore.

Arch Gen Psychiatry. 1981;38(11):1278-1282. doi:10.1001/archpsyc.1981.01780360094011

• To examine the role of the noradrenergic system in anxiety disorders, 23 patients (nine with generalized anxiety disorders and 14 with panic disorders) were studied for four weeks with clonidine hydrochloride, a predominantly presynaptic noradrenergic agonist, and with placebo. A double-blind crossover design was used. The effect of clonidine was comparable in both anxiety disorders and superior to placebo in patients who tolerated the drug. The conditions of 17% of the patients became worse with the medication. The main effect of clonidine was a decrease of anxiety attacks and "psychic" symptoms. Somatic symptoms were least affected. The complexity of the results may be explained through the postsynaptic effects of clonidine, which in part neutralize its presynaptic noradrenergic effects. It may also indicate disturbances in other neurotransmitter systems that are not affected by clonidine.

Barchas JD, Freedman DX:  Brain amines: Response to physiological stress .  Biochem Pharmacol 1963;12:1225.Crossref
Corrodi H, Fuxe K, Lidbrink P, et al:  Minor tranquilizers, stress and central catecholamine neurons .  Brain Res 1971;29:1-16.Crossref
Redmond DE Jr:  Alterations in the function of the nucleus locus coeruleus: A possible model for studies of anxiety , in Hanin I, Usdin E (eds):  Animal Models in Psychiatry and Neurology . New York, Pergamon Press, 1977, pp 293-305.
Redmond DE Jr, Huang YH:  New evidence for a locus coeruleusnorepinephrine connection with anxiety .  Life Sci 1979;25:2149-2162.Crossref
Klein DF, Zitrin CM, Woerner M:  Antidepressants, anxiety, panic, and phobia , in Lipton MA, DiMascio A, Killam KF (eds):  Psychopharmacology: A Generation of Progress . New York, Raven Press, 1978, pp 1401-1410.
Sheehan DV, Ballenger JB, Jacobsen G:  Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms .  Arch Gen Psychiatry 1980;37:51-59.Crossref
Aghajanian GK, Cedarbaum JM, Wang RY:  Evidence for norepinephrine-mediated collateral inhibition of locus coeruleus neurons .  Brain Res 1977;136:570-577.Crossref
Kiser RS, Brown CA, Sanghera MK, et al:  Dorsal raphe nucleus stimulation reduces centrally-elicited fearlike behavior .  Brain Res 1980;191:265-272.Crossref
Stein L, Wise DC, Belluzi JD:  Effects of benzodiazepines on central serotonergic mechanisms .  Adv Biochem Psychopharmacol 1975;14:29-44.
Anden NE, Corrodi H, Fuxe K, et al:  Evidence for a central noradrenaline receptor stimulation by clonidine .  Life Sci 1970;9:513-523.Crossref
Svensson TH, Bunney BS, Aghajanian GK:  Inhibition of both noradrenergic and serotonergic neurons in brain by the a-adrenergic agonist clonidine .  Brain Res 1975;92:291-306.Crossref
Pettinger WA:  Pharmacology of clonidine .  J Cardiovasc Pharmacol 1980;2( (suppl 1) ):S21-S28.Crossref
Svensson TH, Persson R, Wallin L, et al:  Anxiolytic action of clonidine .  Nord Psykiatr T 1978;32:439-441.Crossref
Uhde TW, Post RM, Siever L, et al:  Clonidine: Effects on mood, anxiety, and pain .  Psychopharmacol Bull , to be published.
Leckman JF, Maas JW, Redmond DE Jr, et al:  Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) in man: Preliminary report .  Life Sci 1980;26:2179-2185.Crossref
Gold MS, Redmond DE Jr, Kleber HD:  Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal .  Am J Psychiatry 1979;136:100-102.
Washton AM, Resnick RB:  Clonidine for opiate detoxification: Outpatient clinical trials .  Am J Psychiatry 1980;137:1121-1122.
Simpson GM, Kunz-Bartholini E, Watts TPS:  A preliminary evaluation of the sedative effects of Catapres, a new antihypotensive agent, in chronic schizophrenic patients .  J Clin Pharmacol 1967;7:221-225.
Sugerman AA:  A pilot study of ST-155 (Catapres) in chronic schizophrenics .  J Clin Pharmacol 1967;7:226-228.
Jimerson DC, Post RM, Stoddard FJ, et al:  Preliminary trial of the noradrenergic agonist clonidine in psychiatric patients .  Biol Psychiatry 1980;15:45-57.
Jouvent R, Lecrubier Y, Puech AJ, et al:  Antimanic effect of clonidine .  Am J Psychiatry 1980;137:1275-1276.
Lipman RS, Covi L, Smith VK, et al:  Pharmacotherapy of anxiety and depression .  Psychopharmacol Bull , to be published.
Mountjoy CQ, Roth M, Garside RF, et al:  A clinical trial of phenelzine in anxiety depressive and phobic neuroses .  Br J Psychiatry 1977;131:486-492.Crossref
Kellner R, Uhlenhuth EH, Glass RM:  Clinical evaluation of antianxiety agents: Subject-own-control designs , in Lipton MA, DiMascio A, Killam KF (eds):  Psychopharmacology: A Generation of Progress . New York, Raven Press, 1978, pp 1391-1400.
Hamilton M:  The assessment of anxiety states by rating .  Br J Med Psychol 1959;32:50-55.Crossref
Spielberger CD, Gorsuch RL, Lushene RE:  Manual for the State-Trait Anxiety Inventory . Palo Alto, Calif, Consulting Psychologists Press, 1970.
Hoehn-Saric R:  Characteristics of chronic anxiety patients , in Klein DF, Rabkin J (eds):  Anxiety: New Research and Changing Concepts . New York, Raven Press, 1981, pp 399-409.
Derogatis LR:  Affects Balance Scale (ABS) . Baltimore, Clinical Psychometric Research, 1975.
Andrejak M, Pommier Y, Mouille, et al:  Effects of some μ-adrenoreceptor agonists and antagonists on the guinea-pig ileum .  Naunyn Schmiedebergs Arch Pharmacol 1980;314:83-87.Crossref
Drew GM, Gower AJ, Marriott AS:  Alpha, adrenoreceptors mediate clonidine-induced sedation in the rat .  Br J Pharmacol 1979;67:133-141.Crossref
Paalzow G:  Development of tolerance to the analgesic effect of clonidine in rats: Cross-tolerance to morphine .  Naunyn Schmiedebergs Arch Pharmacol 1978;304:1-4.Crossref
Cohen DJ, Detlor J, Young JG, et al:  Clonidine ameliorates Gilles de la Tourette syndrome .  Arch Gen Psychiatry 1980;37:1350-1357.Crossref
Haefely WE:  Behavioral and neuropharmacological aspects of drugs used in anxiety and related states , in Lipton MA, DiMascio A, Killam KF (eds):  Psychopharmacology: A Generation of Progress . New York, Raven Press, 1978, pp 1359-1374.
Davis M, Redmond DE Jr, Baraban JM:  Noradrenergic agonists and antagonists: Effects on conditioned fear as measured by the potentiated startle paradigm .  Psychopharmacology 1979;65:111-118.Crossref
File SE, Deakin JFW, Longden A, et al:  An investigation of the role of the locus coeruleus in anxiety and agonistic behavior .  Brain Res 1979;169:411-420.Crossref
Mason ST, Fibiger HC:  Anxiety: The locus coeruleus disconnection .  Life Sci 1979;25:2141-2147.Crossref